Composition for upper respiratory tract infection and application thereof

A technology of upper respiratory tract and composition, applied in the field of composition of upper respiratory tract infection, can solve the problems of affecting work and life, accompanied by serious complications, high morbidity and infectivity, etc., and achieve the effect of good curative effect

Active Publication Date: 2020-04-10
JIANGSU KANION PHARMA CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the disease has a high incidence and is contagious to a certain extent, which not only affects work and life, but can sometimes be accompanied by serious complications, and should be actively prevented and treated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for upper respiratory tract infection and application thereof
  • Composition for upper respiratory tract infection and application thereof
  • Composition for upper respiratory tract infection and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Preparation of chlorogenic acid and artemisinone composition

[0021] Composition 1: Accurately weigh 0.333g of chlorogenic acid and 0.667g of artemisinone, add 10ml of physiological saline and mix well, and pass through a 0.22μm filter membrane to sterilize.

[0022] Composition 2: Accurately weigh 0.5g of chlorogenic acid and 0.5g of artemisinone, add 10ml of normal saline and mix well, pass through a 0.22μm filter membrane to sterilize it.

[0023] Composition 3: Accurately weigh 0.667g of chlorogenic acid and 0.333g of artemisinone, add 10ml of physiological saline and mix well, and pass through a 0.22μm filter membrane to sterilize.

Embodiment 2

[0024] Example 2 Anti-inflammatory activity of composition

[0025] 1 Experimental materials

[0026] 1.1 cell line

[0027] The mouse macrophage cell line RAW 264.7 was purchased from Shanghai Cell Bank of Chinese Academy of Sciences.

[0028] 1.2 Drugs and reagents

[0029] DMEM / HIGH GLUCOSE, Gibco;

[0030] FBS: Gibco,

[0031] LPS: sigma;

[0032] Poly I:C:Sigma

[0033] DMSO: sigma;

[0034] 0.25% Trypsin-EDTA: Gibco

[0035] NO detection kit: Biyuntian, product number: S0021;

[0036] Mouse IL-6 detection kit: invitrogen, Lot:1913800020;

[0037] Mouse TNF-α detection kit: invitrogen, Lot: 184786017;

[0038] Mouse PGE2 detection kit: Enzo Life Sciences, Lot: 08211709C.

[0039] 1.3 Experimental equipment

[0040] CO 2 Cell incubator: thermo company;

[0041] Nikon TS100 inverted microscope: Nikon;

[0042] Ultra-clean workbench: Suzhou Aklin Purification Equipment Co., Ltd.;

[0043] Microplate reader: Molecular Devices;

[0044] Pipette: Eppendorf;

[0045] Centrifuge: Hunan Xiangyi Laboratory ...

Embodiment 3

[0065] Example 3 Antibacterial activity of the composition

[0066] 1. Experimental materials

[0067] 1.1 strain

[0068] Streptococcus hemolyticus ATCC32210

[0069] Haemophilus influenzae, ATCC49247

[0070] Streptococcus pneumoniae ATCC49619

[0071] Staphylococcus aureus ATCC25923

[0072] 1.2 Drugs and reagents

[0073] Nutrient broth medium for the cultivation of Staphylococcus aureus

[0074] Brain Heart Infusion Broth (BHI) medium for the cultivation of Haemophilus influenzae

[0075] Mueller-Hinton medium for culture of hemolytic streptococcus and streptococcus pneumoniae

[0076] 1.3 Experimental equipment

[0077] CO 2 Cell incubator: thermo company;

[0078] Ultra-clean workbench: Suzhou Aklin Purification Equipment Co., Ltd.;

[0079] Microplate reader: Molecular Devices;

[0080] Pipette: Eppendorf;

[0081] 2 experimental steps

[0082] 2.1 Minimum inhibitory concentration detection

[0083] Measured by microdilution method. Scrape the fresh colonies grown on the plate with a cotton...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a composition for upper respiratory tract infection. The composition is characterized by comprising the following components in parts by weight: 1-5 parts of chlorogenic acid and 1-5 parts of artemisone. Experiments show that the composition provided by the invention can significantly inhibit LPS or PolyI: C induced generation of inflammatory factors of macrophages RAW 264.7, and has certain bacteriostatic activity on staphylococcus aureus, haemophilus influenzae, streptococcus pneumoniae and hemolytic streptococcus, and in-vitro and in-vivo experiments also show that the composition has the activity of inhibiting influenza viruses.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and particularly relates to a composition for upper respiratory tract infection and its application. Background technique [0002] Upper respiratory tract infection refers to acute inflammation of the outer nostril to the lower edge of the cricoid cartilage, including the nasal cavity, pharynx or larynx. The main pathogens are viruses and a few are bacteria. The incidence is regardless of age, sex, occupation and region, and people with low immune function are susceptible. Usually the disease is mild, short course, self-healing, and good prognosis. However, the disease has a high incidence and a certain degree of contagiousness, which not only affects work and life, but sometimes can be accompanied by serious complications, which should be actively prevented. [0003] About 70%-80% of acute illnesses are caused by viruses, including rhinovirus, coronavirus, adenovirus, influenza virus and parainflue...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/121A61P11/00A61P31/04A61P31/12A61P31/16A61P29/00
CPCA61K31/216A61K31/121A61P11/00A61P31/04A61P31/12A61P31/16A61P29/00A61K2300/00
Inventor 肖伟徐君曹泽彧杨彪曹亮王振中
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap